Randomized phase II study of Valproic acid + weekly paclitaxel in unresectable advanced/recurrent gastric cancer
Phase 2
- Conditions
- Patients with unresectable advanced/recurrent gastric cancer
- Registration Number
- JPRN-UMIN000005887
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pregnant women or women who like to be pregnant 2) History of allergy against Cremophol EL 3) Intestinal pneumonia, lung fibrosis, and severe COPD 4) Clinically important infection or acute inflammation 5) Psychological disease 6) Other severe complication or malignancy 7) CNS metastasis 8) Doctor's dicision not to be registered to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method progression free survival response rate
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link Valproic acid and paclitaxel in gastric cancer treatment?
How does Valproic acid + paclitaxel compare to standard chemotherapy in advanced gastric cancer survival rates?
Which biomarkers correlate with response to Valproic acid-paclitaxel combination in HER2-negative gastric cancer?
What are the most common adverse events of Valproic acid and paclitaxel in Japanese gastric cancer patients?
Are there alternative HDAC inhibitors combined with taxanes for unresectable gastric cancer beyond Valproic acid?